- Home
- » Tags
- » Tositumomab
Top View
- Open Full Page
- (INN) for Biological and Biotechnological Substances
- Bladder Cancer
- Development of Novel Anti-Cd20 Monoclonal Antibodies And
- Y90 Ibritumomab Tiuxetan and I131 Tositumomab
- Federal Register/Vol. 76, No. 5/Friday, January 7, 2011/Notices
- Radioimmunoconjugates
- BEXXAR (Tositumomab and Iodine I 131 Tositumomab) Label
- The Evolution of Antibodies Into Versatile Tumor-Targeting Agents
- Trastuzumab-DM1: a Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer Myra F
- Brentuximab Vedotin and Diffuse Large B-Cell Lymphoma
- 1112-01-Grillo-Lopez-11.6.Mm
- Antibody Therapy of Cancer
- Association Between Gvhd and Nivolumab in the FDA Adverse Event Reporting System
- Tositumomab and I-131
- Pharmacology Update 2021
- Kinase Inhibitors and Monoclonal Antibodies in Oncology: Clinical Implications
- Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody
- Oncology Therapy for the Generalist
- Target Treatment and Symptoms Management
- Adverse Events to Monoclonal Antibodies Used for Cancer Therapy Focus on Hypersensitivity Responses
- Combination of LBH589 with HSP 90 Inhibitors for Treating Cancer
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal
- Immunotherapy and Target Therapy in Non-Hodgkin Lymphoma
- Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy
- Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
- Radioimmunotherapy of Lymphoma
- Ofatumumab, a Second- Generation Anti-CD20 Monoclonal Antibody, For
- Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
- BEXXAR (Tositumomab and Iodine I 131 Tositumomab)
- Tumor-Targeted Drug Conjugates As an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
- Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
- Heart of Darkness: the Downside of Trastuzumab
- Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Working Minutes of the Ephmra Classification Committee
- Tositumomab and Iodine I 131 Tositumomab (Bexaar) Therapeutic Regimen Targets Mono- S.K
- Chemotherapeutics Stolbach
- Panitumumab Modified with Metal Chelating Polymers (Mcps) Complexing Indium‐111 and Lutetium-177 As Theranostics for Pancreatic Cancer
- Radioimmunotherapy Consolidation Using I-Tositumomab for Patients
- Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations a Coulson, a Levy, M Gossell-Williams
- Update on the Rational Use of Tositumomab and Iodine-131 Tositumomab Radioimmunotherapy for the Treatment of Non-Hodgkin’S Lymphoma
- How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy by Jon Gingrich, Ph.D
- Tositumomab and 131I Therapy in Non-Hodgkin's Lymphoma